Top Anti Cancer Imported Medicine Drugs in India - Pharma Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Welireg  (Belzutifan + Lenvatinib) Medicine in India

Welireg (Belzutifan + Lenvatinib)

Medicine name : Welireg

Generic name : Belzutifan + Lenvatinib

Manufactured By : Merck & Co., Inc. / Eisai Inc.

Indications : Treatment of adults with advanced renal cell carcinoma (RCC) with a clear cell component (ccRCC) following a PD-1 or PD-L1 inhibitor.

Medicine Description : A targeted combination therapy for adults with advanced clear cell renal cell carcinoma (RCC) following PD-1 or PD-L1 inhibitor treatment. Welireg (Belzutifan) combined with Lenvima (Lenvatinib) works by blocking HIF-2α and tumour growth-related pathways, helping slow cancer progression.

Product Introduction

Welireg (Belzutifan), used in combination with Lenvima (Lenvatinib), is a targeted anticancer treatment for adults with advanced renal cell carcinoma (RCC) containing a clear cell component (ccRCC) following treatment with a PD-1 or PD-L1 inhibitor. Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, while lenvatinib is a multi-targeted tyrosine kinase inhibitor. Together, these medicines target pathways involved in cancer-cell growth and tumour blood supply.

The recommended combination dose is 120 mg of belzutifan and 20 mg of lenvatinib, taken orally once daily. Treatment generally continues until the cancer progresses or side effects become unacceptable. Regular medical assessments and blood tests are essential to monitor treatment response, blood counts, oxygen levels, blood pressure and heart function.

Common side effects may include anaemia, fatigue, muscle and joint pain, decreased lymphocyte counts, increased liver enzymes, nausea, headache, dizziness and shortness of breath. Serious risks include severe anaemia, low oxygen levels (hypoxia), cardiac dysfunction, high blood pressure, kidney or liver problems and embryo-fetal harm. Patients should report breathing difficulties, chest pain, unusual swelling, severe fatigue or other concerning symptoms promptly.

Uses Of Welireg (Belzutifan + Lenvatinib)

Treatment of Advanced Renal Cell Carcinoma (RCC)

Benefits Of Welireg

Welireg (Belzutifan), in combination with Lenvima (Lenvatinib), is used to treat adults with advanced renal cell carcinoma containing a clear cell component whose disease has progressed following treatment with a PD-1 or PD-L1 inhibitor. Belzutifan blocks HIF-2α activity, while lenvatinib inhibits multiple tyrosine kinases involved in tumour growth and blood vessel formation.

Side Effects Of Welireg (Belzutifan + Lenvatinib)

Some side effects of Welireg (Belzutifan) in combination with Lenvima (Lenvatinib) may be manageable during treatment. Inform your doctor if any side effect persists, worsens, or becomes troublesome.

Common Side Effects of Welireg (Belzutifan + Lenvatinib)

  • Fatigue or unusual tiredness
  • High blood pressure (hypertension)
  • Muscle and joint pain
  • Diarrhea
  • Nausea
  • Vomiting
  • Decreased appetite
  • Constipation
  • Abdominal pain
  • Skin rash
How To Use Welireg

Take Welireg (Belzutifan) 120 mg and Lenvima (Lenvatinib) 20 mg orally once daily, exactly as prescribed by your oncologist. Both medicines can be taken with or without food. Take them at approximately the same time each day. Swallow Welireg tablets whole and follow the prescribed instructions for Lenvima capsules. Continue treatment until disease progression or unacceptable side effects. Regular blood tests, oxygen-level checks, blood pressure monitoring and heart assessments may be required.

How Welireg (Belzutifan + Lenvatinib) Works

Belzutifan blocks hypoxia-inducible factor-2 alpha (HIF-2α), a protein that helps cancer cells survive and grow under low-oxygen conditions. Lenvatinib inhibits multiple tyrosine kinase receptors, including VEGF and FGF receptors, involved in tumour growth and blood vessel formation. By targeting these pathways together, the combination helps restrict cancer-cell growth and tumour blood supply.

Storage Conditions
  • Store both Welireg and Lenvima at room temperature between 20°C and 25°C.
  • Temporary temperature excursions between 15°C and 30°C are permitted
  • Keep Welireg in its original bottle with the desiccant canisters to protect the tablets from moisture. Do not consume the desiccants
  • Keep Lenvima in its original blister packaging and store both medicines in a dry place, away from excessive heat and out of reach of children
Safety Advice

AlcoholAlcohol CONSULT YOUR DOCTOR

Avoid excessive alcohol consumption during treatment. Consult your doctor before drinking alcohol, as it may worsen side effects such as dizziness, fatigue and nausea.

PregnancyPregnancy CONSULT YOUR DOCTOR

Welireg may cause harm to an unborn baby. Avoid use during pregnancy. Women who can become pregnant should use effective non-hormonal contraception during treatment and follow the longer contraception period required by the combination treatment.

BreastfeedingBreastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment or for the post-treatment period specified by the prescribing information of both medicines. Consult your doctor before breastfeeding again.

DrivingDriving CONSULT YOUR DOCTOR

Welireg with Lenvima may cause fatigue, dizziness, weakness or other effects that can impair alertness. Avoid driving or operating machinery if affected.

KidneyKidney CAUTION

Inform your doctor if you have kidney disease. Regular kidney function tests and urine protein monitoring may be required during treatment.

LiverLiver CAUTION

Inform your doctor about any existing liver condition. Liver enzyme changes may occur, so regular liver function tests may be recommended.

Quick Tips
  • Take both medicines once daily at the same time, exactly as prescribed by your oncologist.
  • Swallow the tablets and capsules according to their prescribed instructions; do not crush or chew them.
  • Attend regular blood tests to monitor haemoglobin, kidney function and liver function.
  • Monitor your blood pressure and oxygen levels as advised by your doctor.
  • Report unusual tiredness, breathing difficulties, chest pain or abnormal bleeding promptly.
  • Read More About - Welireg (Belzutifan + Lenvatinib) from Pharma Five.
About Pharma Five

Pharma Five helps patients seeking Welireg (Belzutifan) with Lenvima (Lenvatinib) by facilitating the import of limited quantities for individual medical requirements, in accordance with applicable regulations. Depending on the case, the process may require Form 12A, a valid prescription from a Registered Medical Practitioner (RMP), and other supporting documents.

Drawing on more than 20 years of pharmaceutical industry experience, Pharma Five provides medicine consultancy and import assistance for patients requiring specialised treatments such as Welireg with Lenvima. The team guides patients through the relevant documentation and import formalities to help them understand the process of accessing these medicines. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

References
  1. https://go.drugbank.com/drugs/DB15463
  2. https://go.drugbank.com/drugs/DB09078
Faq

General Question

Welireg (Belzutifan) with Lenvima (Lenvatinib) is a targeted combination treatment for adults with advanced renal cell carcinoma (RCC) containing a clear cell component after treatment with a PD-1 or PD-L1 inhibitor.

Belzutifan blocks the HIF-2α protein involved in cancer-cell growth, while lenvatinib blocks multiple tyrosine kinase receptors involved in tumour growth and blood vessel formation.

This combination is prescribed for adults with advanced clear cell renal cell carcinoma following treatment with a PD-1 or PD-L1 inhibitor.

Take Welireg and Lenvima orally once daily at the prescribed doses. Welireg tablets should be swallowed whole, and Lenvima capsules should be taken according to the prescribed instructions.

Common side effects include fatigue, high blood pressure, muscle and joint pain, diarrhoea, nausea, vomiting, decreased appetite, constipation, abdominal pain and skin rash.

Yes. Serious side effects may include anaemia, low oxygen levels, heart dysfunction, severe bleeding, kidney problems and liver complications. Contact your doctor if concerning symptoms occur.

Continue treatment until the cancer progresses or side effects become unacceptable, as determined by your oncologist.

Consult your doctor before consuming alcohol during treatment. Avoid excessive alcohol consumption, particularly if you experience dizziness, fatigue or nausea.

Welireg may cause harm to an unborn baby. Pregnancy should be avoided during treatment, and effective non-hormonal contraception should be used as advised by your doctor.

Welireg and Lenvima may interact with other medicines, including certain prescription drugs and supplements. Inform your doctor about everything you take before starting treatment.

For a missed Welireg dose, take it as soon as possible on the same day and resume the regular schedule the next day. If a missed Lenvima dose cannot be taken within 12 hours, skip it and take the next dose at the usual time. Never double a dose.

Yes. Both Welireg and Lenvima may be taken with or without food. Take them at approximately the same time each day.

Attend regular blood tests and monitor blood pressure, oxygen levels, kidney and liver function. Report breathing difficulties, chest pain, unusual bleeding or severe fatigue promptly.

Store Welireg and Lenvima at room temperature between 20°C and 25°C, with permitted excursions between 15°C and 30°C. Keep both medicines in their original packaging and protect them from moisture.

Pharma Five may assist patients seeking Welireg with Lenvima through pharmaceutical consultancy and medicine import support, subject to applicable regulations and required medical documentation. Pharma Five assists in its procurement.

Timely Service
Doorstep Delivery
Hassle-Free Process
100% Genuine Sources